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OVERVIEW 
 
The pattern and global burden of disease has evolved considerably over the last two 
decades, from primarily communicable, maternal, and perinatal causes to non-
communicable disease (NCD).  Cardiovascular disease (CVD) has become the single 
most important and largest cause of NCD deaths worldwide at over 50%. The World 
Health Organization (WHO) estimates that 17.6 million people died of CVD 
worldwide in 2012. Proportionally, this accounts for an estimated 31.43% of global 
mortality, with ischaemic heart disease (IHD) accounting for approximately 7.4 
million deaths, 13.2% of the total. IHD was also the greatest single cause of death in 
2000, accounting for an estimated 6.0 million deaths. The global burden of CVD falls, 
principally, on the low and middle-income (LMI) countries, accounting for over 80% 
of CVD deaths. Individual populations face differing challenges and each population 
has unique health burdens, however, CVD remains one of the greatest health 
challenges both nationally and worldwide.  
  
Introduction 
Global disease burden has changed considerably over the last two decades. The 
worldwide health burden has shifted from communicable, maternal and perinatal 
causes to non-communicable diseases (NCD)1, 2 with cardiovascular diseases (CVD) 
being the largest single contributor worldwide.1, 3 This tendency is explained by the 
concept of the ‘epidemiological transition’, whereby the socio-economic development 
of a region causes a general shift from communicable to non-communicable disease.  
The WHO estimates 17.6million people died of CVD globally in 2012, representing a 
substantial increase from 2000.4 The burden of CVD is also considerably contributing 
to life years lost to disability.5 The nature of the CVD burden is not distributed 
equally across the world and represents different challenges dependent on factors such 
as culture, risk factor prevalence, ethnicity, economics and geography.6 
Understanding the global impact of CVD burden and causative factors allow 
international health groups and governments to plan public health strategies and 
interventions to combat the growing global burden. The aim of this review is to assess 
and analyse the changes in CVD health burden over the last twelve years using the 
global health estimates data from the WHO and World Bank 5,7,8 and to examine the 
risk factor prevalence and possible associations. 
 
Methodology 
This is a secondary data analysis of the 2000 and 2012 global health estimates 
published by the WHO and World Bank. Only aggregate data of absolute numbers, 
rates and percentages of subjects falling into categories were made available and thus 
analysed. Wald confidence intervals are presented for proportions and comparisons of 
the proportion of deaths attributed to diseases are made using Wald tests or Pearson’s 
Chi-squared tests and logistics regression for factors with more than two categories 
such as region. For ordinal variables the Cochran-Armitage trend test is used. The 
statistical analysis was conducted using SAS v9.4 TS1M2. 
 
Metrics of CVD Health Burden and Limitations of the WHO data 
To evaluate the extent of the CVD global burden a standard set of definitions and 
metrics must be rigorously applied. All WHO member states use the International 
Classification of Diseases Tenth edition (ICD-10), translated into 43 different 
languages.9 The ICD-10 is used to code all health diagnoses and most member states 
use it to define primary mortality.9 Despite its widespread use, ICD-10 is not used by 
every member state and only 60 countries meet the inclusion criteria to admit 
statistics to the WHO mortality database.10 Furthermore, not all mortality statistics 
admitted to WHO are coded to the same standard.10 Table 1 demonstrates all subset 
diagnoses that contribute to CVD total as per ICD-10 coding, except ‘congenital heart 
anomalies’ which is of the ‘congenital anomalies’ ICD-10 category.9 Throughout this 
review ‘congenital heart anomalies’ will be discussed with CVD burden, but not 
contribute to the total metrics presented.  
 
The highest standard of submitted data is from WHO member states that utilise a 
national vital registration system for mortality, allowing real-time health statistics to 
be produced. However, even the highest standard systems suffer from data that is 
partially inaccurate.11 Studies have demonstrated disparity between diagnosis on 
death certificate and actual cause of death in national vital registration systems. 12 
Several WHO member states lack the infrastructure to provide usable/reliable real-
time mortality statistics11 making accurate data on global health challenging. Sample 
vital registration systems have been utilised to overcome this problem.11 These 
systems have been designed to represent a random subset of the population over a 
period of time to infer population based health statistics.11 China and India use sample 
vital registration systems.13 In China the Disease Surveillance Point system is used, 
which represents 1% of the population and India uses a nationally representative 
household survey that monitors for cause of death in a population of over 14 
million.13 However, not all WHO member states have a real-time sampling system in 
place.11 In situations where no previous data is available, other small sources like 
verbal autopsies, disease surveillance systems and analyses from WHO technical 
programs are used.10, 11 Where data is absent or unusable then interpolation and 
extrapolation is used.10 This data can then be used to inform reasonably robust 
prediction models.11  
 
Measurement of disease burden uses several variables.  Mortality rate, whilst a 
critically important measure of health status and disease burden, assigns the same 
value to each death regardless of age.14 Disability Adjusted Life Years (DALY) 
accounts for years of life lost as well as the years of healthy life lost due to a 
condition.14 Lost DALYs represent condition specific fatal and non-fatal disease 
burden, representing the full impact of any given condition. One DALY equates to 
one year of healthy life lost making it a powerful metric in assessing global disease 
burden.14 Both measurements will be utilised in this review to measure CVD burden.  
 
Global Cardiovascular Disease Burden: Mortality 
The percentage of CVD as a proportion of global mortality has increased significantly 
from 28.2% in 2000 to 31.4% in 2012 (p<0.001, table 1).4 Ischaemic heart disease 
(IHD) and stroke represent the top two causes of mortality. Moreover, the gap 
between these and the next leading cause is widening (table 2) with the difference 
estimated to be 4.11% (95% CI [4.10 – 4.12]) in 2000 and 6.39% (95% CI 6.37 – 
6.40). Three CVD categories are in the top 10 causes of global mortality for 2012: 
IHD, stoke and hypertensive heart disease (table 2). CVD mortality is not distributed 
equally across the globe (p<0.001 test of equality of proportions for 2000 and 2012, 
respectively). Figure 1 demonstrates this geographical variation in CVD mortality 
from 2000-2012. Europe is still the frontrunner in CVD mortality despite a decrease 
since 2000. Comparatively, Europe’s mortality rate at 47.9% is higher than the 2012 
global mortality rate.8 Europe, on the WHO global health estimated dataset, is 
classified as including Western Europe and Russian Federation. In 2012, CVD 
mortalities accounted for 59.6% of the total for the Russian Federation, compared to 
30.5% of mortalities in the United Kingdom.8 Such intra-regional differences are also 
apparent in the Americas. A population wide comparative observational study in 
Brazil for IHD mortality demonstrated regional variations in death rates depending on 
economic status over a ten-year period. 15 Comparatively poorer North and Northeast 
regions demonstrated increasing mortality rates compared to a decrease in the South 
and Southeast regions.15 Economic status of a particular country has an important 
impact upon cardiovascular disease mortality rates. 7 The WHO/World Bank classify 
countries by economic status in comparison of health metrics to control this 
significant variable.7 Figure 2 compares mortality rates for NCD and CVD based on 
further sub-classification of World Bank Economic regions into HI and low-middle 
income (LMI) countries for 2000 and 2012.7 All LMI regions assessed demonstrated a 
statistically significant increase in both CVD and NCD mortality during this period 
whilst the proportion of deaths due to CVD in high income countries was falling 
significantly in the same period by 5.50%  [5.46 – 5.54])  .  
 
Variation amongst population occurs between regions and within regions. Figure 3a 
demonstrates, males carry the higher burden overall as they age (p<0001); this is until 
females pass the menopause when CVD mortality burden accelerates more rapidly for 
females.4 There is variation of mortality rates within each gender based on age and 
region (figure 3b and 3c). However, what is consistent across all regions and genders 
is that there is rapid increase in CVD mortality once >60years old (p<0.001 for 
difference in rates between <60 and ≥60 years for all regions expect Africa where 
p=0.012). Of these CVD mortality for the African region is the lowest for males and 
females in older age and reflects an alternative health burden. The CVD burden tends 
to occur at younger ages in Africa.16 The acceleration in mortality rate starts earlier in 
the South Asian region for males at >30years compared with others. No such pattern 
affects South Asian females. Significantly, the rate of tobacco smoking in South Asia 
is much higher in males than females and likely significant contributory factor for the 
discrepancy.1  
 
Global Cardiovascular Disease Burden: DALYs 
CVD accounted 393.8 million (14.4%) of total global DALYs lost in 2012. This is a 
significant increase in the proportion from 12.3%  (352.8 million) in 2000.5 Table 3 
compares DALYS lost for 2000 and 2012 for NCD, total CVD and specific 
cardiovascular subset categories.5 The WHO global health data suggests an overall 
decrease in total lost DALYs between 2000-2012; the contribution of NCD, however, 
has increased driven primarily by CVD. The fatal and non-fatal health burden of 
specific conditions has changed between 2000 and 2012.2 Table 4 represents the top 
10 specific causes of loss of DALYs for 2000 and 2012.2 Importantly, the top ten for 
both years includes chronic medical conditions and mental health problems.2 
Specifically the global disease burden of IHD and stroke has increased between 2000 
and 2012.5 Lower Respiratory Tract Infection (LRTI) in 2000 was the single largest 
cause of loss of DALYs. This had reduced by 2012 where LRTI was the second 
commonest cause of loss of DALYS.2 Interestingly, other CVD conditions like atrial 
fibrillation (AF) and peripheral vascular disease (PVD) have significantly increased 
between 1990 and 2010.2 The change in rankings demonstrates the increasing 
contribution of CVD to fatal and non-fatal health burden worldwide.5  
 
 
The economic status of the WHO member states impacts on the fatal and non-fatal 
NCD including CVD burden. Figure 4 compares rates of lost DALYs for NCD and 
CVD World Banking region in 2000 and 2012. In all LMI regions the number of 
DALYs attributable to NCD and CVD increased from 2000-2012. The LMI regions 
South Asia with East Asia and the Pacific have the greatest increase of DALYs lost 
due to NCD. HI countries had >80% of their DALYs attributed to NCD in 2000 and 
2012.17 DALYs attributable to CVD decrease between 2000-2012. This pattern 
mimics that of NCD and CVD mortality rates (figure 2).  
 
Figure 5a outlines lost DALYs globally classified by gender/age. Overall, males and 
females have respectively lost 216.1 million (14.5%) and 177.7 million (14.1%) 
DALYs attributable to CVD.5 The leading cause of loss of DALYs in males is IHD 
and stroke for females.5 Overall, both genders behave in a similar way, with all 
regions losing more DALYs with increasing age (figures 5b and 5c). This is more 
pronounced in earlier life for males than females. European females have a more 
rapid loss of DALYs in later years, in contrast to males who have a greater loss of 
DALYs in earlier and middle life.5 South East Asian males have a rapid loss of 
DALYs in earlier life than females.5 The Western Pacific region has the greatest loss 
of DALYs with age in both genders.5 The African region demonstrated lowest overall 
loss of DALYs due to CVD. Increased loss of DALY’s with increasing age, per 
gender, is demonstrated but the overall rate of loss is significantly lower than all other 
WHO regions and World Banking regions.5 This suggests alternative reasons for loss 
of DALYS in this region.5  
 
Total health burden has decreased across the world, but the burden of NCD and 
specifically CVD has increased. The World Banking global health estimates report 
suggests HI countries have turned the corner on lost DALYs due to CVD.17 The focus 
of CVD burden is now on LMI countries with all regions increasing from 2000-
2012.17 The African region represents the biggest potential expansion in the future, 
given the projected epidemiological transition and current low contribution to loss of 
DALY’s. This estimate of fatal and non-fatal CVD burden and projection is one of the 
critical factors for world authorities to plan public health strategies to target and tackle 
this problem.    
 
  
Global Risk Factors and Health Conditions Impacting on CVD 
The majority of CVD burden can be attributed to a few specific factors. The 
distribution of these specific risk factors and health conditions vary across the world 
and is associated with the prevalence of CVD. These risk factors include, but are not 
restricted to, hypertension, diabetes mellitus, tobacco smoking, dyslipidaemia and 
alcohol consumption.18 The presence of particular lifestyle risk factors varies between 
countries and explains how ethnic constructs influence CVD burden worldwide. Each 
risk factor is discussed with reference to its global prevalence.  
 
Hypertension 
Worldwide hypertension contributes 7.5million deaths (12.8%) and 5.7million lost 
DALYs (3.7%).1, 19 It is a known risk factor for numerous CVDs and the number with 
uncontrolled hypertension increased from 600million in 1980 to approximately 
1billion in 2008,1, 19 and projected to rise to 1.56billion by 2025 20 with 67.5% of 
patients residing in LMI countries.20  
 
Diabetes Mellitus 
Diabetes Mellitus (DM) is one of the great future health burdens with ever increasing 
numbers being affected. In 2000, approximately 171 million were affected and 
projected to increase by 2030 to an estimated 366 million with the biggest burden in 
the Middle East, Sub-Saharan Africa and India.21 In 2012 DM was responsible for 
approximately 1.5 million deaths worldwide with a third of this in South Asia.7 DM 
accounted for 2.2% of total lost DALYs in 2012.4 Crucially almost 60% of deaths 
from DM are due to CVD.1 
 
Tobacco 
Globally 9% of all NCD mortalities are attributable to tobacco. Smoking poses one of 
the greatest risks for development of CVD.19 Europe has the highest prevalence of 
smokers (31%), the lowest is Africa (10%).22 The WHO global atlas of CVD 
compared rates of smoking in both genders across the world for 2011.1 Overall the 
prevalence of smoking is the same in Eastern Europe and the Russian Federation for 
both genders.1 A higher proportion of males smoke in South-East Asia than females.1 
In Europe and South-America the trend is reversed.1 In 1965, 41.7% of USA adults 
smoked, compared with 19.3% in 2010.3 In Eastern Europe and South-East Asia, 
smoking is the third largest risk for CVD. 2 
 
Dyslipidaemia  
Hypercholesterolaemia increases risk of IHD and stroke23 and is associated with a 
third of all IHD deaths and is estimated to be the cause of 2.6million (4.5%) deaths 
and 29.7million (2.0%) lost DALYs.1,24 In 2008, the global rate of raised total 
cholesterol was 39.0% (male 37.0%/females 40.0%).1 Over 50% of the population of 
HI countries have elevated total cholesterol. There has been no change in mean total 
cholesterol between 1980-2008, with <0.1mmol/L fall per decade.1 The prevalence is 
highest in Europe at 54.0% (both genders), followed by the Americas at 48.0% (both 
genders).1 The lowest prevalence was found in Africa at 23.0% and South-East Asia 
at 30.0% (both genders).19  
 
Physical Activity 
Insufficient physical activity is defined as less than 30 minutes of moderate activity 
per week. Lack of exercise is a leading cause of CVD, especially IHD.3, 25 The impact 
of physical inactivity on the global health burden is 3.2million deaths (5.5%) and 
32.1million lost DALYs (2.1%).24 Individuals who have insufficient activity have 20-
30% increased risk of all-cause mortality.1 Participation in exercise reduces the risk of 
IHD and stroke in a dose dependent fashion.26 The WHO region with greatest 
prevalence of inactivity is the Americas.1 The prevalence of inactivity in HI countries 
is over double that of LMI countries in both men and women.1 Approximately 41.0% 
men and 48.0% of women are inactive in HI countries. In contrast, 18.0% of men and 
21.0% of women are inactive in lower income countries.19 There is little variation in 
inactivity rates between the genders in individual countries.1 
 
Alcohol 
Alcohol consumption is associated with development of CVD.25 Dangerous 
consumption of alcohol was responsible for 2.5million deaths (3.6%) in 2004, over 
half due to CVD, liver cirrhosis and cancer.1, 24 In all regions of the world it 
contributes to prevalence of CVD, with more significant contribution in LMI 
countries.1 Eastern Europe has high alcohol consumption and is the fifth largest 
contributor to CVD.27 Interestingly, in other regions alcohol is not as high a 
contributor to CVD burden.2 Traditionally, alcohol was thought to be cardio-
protective, a view immortalised by the 1996 WHO/World Bank report on global 
burden of disease that “alcohol is cardio-protective at all levels of consumption”.28 A 
large meta-analysis was performed to reconcile the conflict between the cardio-
protective role of alcohol outlined in the West and association between consumption 
and CVD in Eastern Europe.29 The study demonstrated that problematic drinking was 
the key risk factor.29 The analysis demonstrated a strong association between excess 
alcohol consumption, arrhythmias and sudden cardiac death.29 A case-control study 
from Moscow demonstrated higher rate of sudden cardiac deaths at weekends, 
coinciding with higher rates of alcohol consumption.30 Alcohol consumption patterns 
are causative for CVD and in particular sudden cardiac death. 30 Traditionally, Eastern 
Europe and the Russian Federation drink alcohol in a pattern of heavy binges, partly 
explaining the level of impact of alcohol consumption in their regions. 
 
Ethnicity & Region Populations 
European 
European populations are diverse as are their experiences of CVD mortality and 
burden. Eastern Europe has higher fatal and non-fatal CVD burden, for both genders, 
compared with other European populations.31 The Russian Federation has a six-fold 
higher CVD mortality than France.31 This stark difference is largely attributable to 
lifestyle risk profiles with higher rates of CVD burden in Eastern Europe linked to 
higher rates of smoking, alcohol consumption, diets high in saturated fats and poor 
social circumstances.31 Interestingly, the relatively low IHD incidence in Southern 
European countries is hypothesised to be due to the consumption of mono-unsaturated 
fats, such as olive oil.32 Paradoxically, the higher consumption of wine has been 
linked to lower incidence of IHD in France.32 Many Western European countries have 
experienced a reduction in CVD over recent decades, attributed largely to better 




Compared to Western Europe, China suffers 50% higher mortality from CVD.31 The 
Monitoring Trends and Determinants in Cardiovascular Disease (MONICA) study 
identified haemorrhagic strokes were 2-3 times higher in Chinese compared with 
white Caucasian populations.33 Tobacco smoking is high amongst Chinese males and 
contributes to high CVD burden.33 There may be genetic components that predispose 
Chinese populations to CVD, evidenced by the direct correlation of cholesterol to 
IHD mortality despite lower serum cholesterol in the Chinese.34  
 
 South Asian  
This region includes people originating from India, Sri Lanka, Bangladesh, Nepal and 
Pakistan.31 Though accurate record keeping is challenging, especially in India31, the 
WHO/World Bank epidemiological modelling estimates India to have the second 
highest CVD mortality worldwide, at >2.5million per year.35 Furthermore, the burden 
of CVD in India is set to increase, with DM expected to increase from 2000-2030 by 
40%.31 Various studies have demonstrated migrant South Asian populations 
experience increased risk of CVD compared to the native populace despite similar 
levels of exposure to risk factors as the indigenous populations.36  
 
Hispanic 
This includes Americans of Cuban, Mexican and Puerto Rican descent. They account 
for 16.3% of the USA population.37 Globally, CVD accounts for 28% of male and 
34% of female Hispanic mortality.31 The USA Hispanic population have a higher 
prevalence of classic risk factors in both genders, such as hypertension, smoking, 
elevated cholesterol, DM and obesity.31 The USA Hispanic population has a higher 
incidence of acute myocardial infarction than non-Hispanic americans.31 This risk is 




The Sub-Saharan Africa population varies significantly to other groups of black 
people of African origin. Atherosclerosis only causes half of all CVD burden here 
which is lower than all other regions.16 The leading cause of death is stroke, 38.8% in 
2010,16 but despite this Sub-Saharan Africa has the lowest mortality rate due to CVD 
globally at only 10.0%, as recorded in 2012.7 Sub-Saharan Africa also has the lowest 
number of years of life lost to CVD6, accounting for only 3.5% of total lost DALYs in 
this region.17 As a region undergoes socio-demographic development the 
epidemiological profile and burden of disease changes38, there is a tendency from 
communicable to NCD as countries grow economically.38 The unusual profile for 
Sub-Saharan Africa may be explained by it being at an earlier stage of 
epidemiological transition with lower average life expectancy (58years for both 
genders).39 As a result CVD burden has a different pattern and occurs at younger 
ages16, and traditional IHD risk factor burden is lower.40 It must be acknowledged that 
much of this information is based on epidemiological modelling to account for data 
depletion or absence, some caution in its interpretation is therefore warranted.6 CVD 
is of particular concern future of African populations as they progress through stages 
of epidemiological transition and the process of urbanisation accelerates. With 
increasing urbanisation comes increased exposure to risk factors such as hypertension 
and hypercholesterolaemia, which has already been attested within the black 
population of South Africa.31 Urbanisation rates are projected to increase globally and 
with this CVD burden will follow. The concept of the epidemiological transition is 
useful for describing the paradigm change in disease burden but does not supplant 
country-specific lost DALYs profile as a means of informing health policy 
decisions.38 
 CVD Global Burden of Individual Conditions 
Ischaemic Heart Disease 
IHD was the single greatest cause of fatal and non-fatal global disease burden in 2012 
with an estimated 165million lost DALYs, which accounts for 6.0% of the total.5 The 
burden of IHD has increased from 2000, when the largest single cause of lost DALYs 
was LRTIs accounting for 7.3% of the total.5 Globally, there are large variations in 
total burden of IHD. When the WHO regions are stratified by the world banking 
organisation income status classification, the highest proportion of lost DALYs 
attributed to IHD in 2012 was in the LMI South-East Asia region at 26.0%.17 The 
LMI Africa and America regions had the lowest proportion of lost DALYs 
attributable to IHD, both 6%.17 Figures 6a and 6b show the WHO/World Bank 
regions contribution to the worldwide IHD DALYs lost in 2000 and 2012 
respectively.17 The reduction in DALYs lost in HI countries reflects improvements in 
healthcare and primary prevention. The significant increases in the LMI South-East 
Asia and Western Pacific regions reflect an aging population, increasing exposure to 
lifestyle risk factors and more effective treatment of other health conditions. During 
2012, the LMI South-East Asia region had a much larger proportion of men than 
women affected by IHD.17 The significant gender difference in South-East Asia is 







Atrial fibrillation (AF) is the commonest cardiac arrhythmia worldwide.41 The global 
burden of AF is very difficult to estimate as statistics are based on epidemiological 
studies from North America and Europe42 with the populations recruited being mainly 
white Caucasians. In the UK, the West Birmingham-AF project demonstrated a 
prevalence of 2.4% in white Caucasians and 0.6% among Indo-Asians.43 Furthermore 
other studies suggest the proportion of AF in black populations is lower.41 Lip et al. 
performed a systematic review to identify and collate the current evidence.41 The 
estimated prevalence of AF ranged from 0.1% in India to 4% in Australia.41 The 
prevalence in Japan was fairly consistent between 0.6-1.6%. 41 The Chinese and Thai 
community cohorts were more variable, ranging from 0.8%-2.8% and 0.4%-2.2%, 
respectively.41 Lip et al, demonstrated the majority of studies associate increasing age 
in all populations with AF prevalence.41 It is for this reason that Rahman et al 
predicted AF prevalence to double in rapidly developing countries such as India, 
Brazil, Indonesia, China and Bangladesh.44 
 
Heart Failure 
Heart failure (HF) is a heterogeneous condition and can be the result of various 
CVDs. IHD is the predominant cause of CVD in high income nations and non-
ischaemic cardiomyopathy and rheumatic heart disease are more common in 
developing countries.45 Specific consideration must be given to Chagas disease in 
Latin America as it is the commonest cause of non-ischaemic cardiomyopathy in the 
region. 46 There are 6-7 million cases of Chagas disease, with an estimated 25-41% of 
patients developing HF.46, 47  
 
The challenge in estimating HF’s specific global burden is partly due to lack of 
uniformity in making the diagnosis. ICD-10 does not clearly define HF as a separate 
diagnosis and as such HF is not examined in the GBD study.9, 14 HF affects 
approximately 26 million people worldwide48 and has an estimated 30-40% mortality 
within the first year of diagnosis.49 However, 6-month mortality rate decreased from 
26% in 1995 to 14% in 2005.50 The hospitalisation rate for HF patients is high. In 
Europe and USA, HF is a leading cause of hospitalisation.50 This accounts for 
>1million hospital admissions representing 1-2% of all hospitalisations.52 It is 
estimated that hospital admissions due to heart failure will rise by 50% over the next 
25 years52 meaning, irrespective of the issues in classification, the condition is one 
that cannot be ignored in the future of CVD burden. 
 
Congenital Heart Disease 
Congenital Heart Disease (CHD) is defined as a clinically significant structural heart 
disease present at birth.53 It is a major cause of morbidity and mortality worldwide. In 
2012, an estimated 230,000 deaths were attributable to CHD.4 In 2000, the number of 
estimated deaths was higher at 234,000, but both years the proportion remained the 
same at 0.4%.4 CHD in 2012 was the cause of an estimated 19.8million lost DALYs, 
which was a reduction from 2000 figures that totalled 20.3million.5 Proportionally 
this remained the same in both years at 0.7%.5 The incidence of CHD has increased, 
due to the ability to diagnose milder forms of disease that do not cause long-term 
problems.53 The current incidence is estimated at 10-12 per 1000 live births.53 These 
figures do not appear congruent with the decline in absolute numbers of mortality and 
loss of DALYs globally. Between 1990-2010 there has been a reduction in loss of 
DALYs.2 Globally, these numbers reflect a greater rate of diagnosis, reflecting better 





The patterns of CVD are likely to change, particularly in developing countries. Africa 
is likely to follow the trends seen in the Indian subcontinent with increasing 
urbanisation influencing physical activity and diet, as well as improvement in 
management of communicable diseases leading to more coronary events. Whilst not 
true for all regions, there is a tendency toward increased CVD burden as the lower 
income nations progress through the epidemiological transition and the prevalence of 
key risk factors in these populations increases. The impending worldwide epidemic of 
DM and AF will have significant roles to play, impacting heavily on global burden of 
coronary disease and HF. CVD currently represents a leading NCD and is set to 
remain the most significant global health burden for decades to come. 
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 Table 1: Global CVD Mortality: 2000 and 2012.  





Deaths  (%) 
2000 







































Rheumatic heart disease 
Hypertensive heart disease 
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Other circulatory diseases* 1,623,500 (3.07) 






All percentages represent a proportion of total all cause mortality for that 
respective year 
















Table 2: Top 10 Global Causes of Morality in 2000 and 2012.  
Source: World Health Organization. Comparison of rates between regions 20144  
2000 
 
Rank Cause Deaths (%) [CI] 
Deaths/100,000 
population 
0 All Causes 52,806,020  (100.0%) 862.3 
1 Ischaemic heart disease 
5,974,060 (11.3%) [11.30 – 
11.32] 97.6 
2 Stroke 
5,661,550 (10.7%) [10.71 – 
10.73] 92.5 
3 Lower respiratory infections 3,490,570 (6.61%) [6.60 – 6.62] 57.0 
4 
Chronic obstructive 
pulmonary disease 3,059,320 (5.79%) [5.79 – 5.80] 50.0 
5 Diarrhoeal diseases 2,171,250 (4.11%) [4.11 – 4.12] 35.5 
6 HIV/AIDS 1,678,220 (3.18%) [3.17 – 3.18] 27.4 
7 Tuberculosis 1,343,080 (2.54%) [2.54 – 2.55] 21.9 
8 Preterm birth complications 1,316,100 (2.49%) [2.49 – 2.50] 21.5 
9 
Trachea, bronchus, lung 
cancers 1,164,430 (2.21%) [2.20 – 2.21] 19.1 
10 Diabetes mellitus 1,045,760 (198.%) [1.98 – 1.98] 17.1 
2012 
Rank Cause Deaths (%) 
Deaths/100,000 
population 
0 All Causes 55,858,720 (100.0%) [CI] 789.5 
1 Ischaemic heart disease 
7356060 (13.17%) [13.16 – 
13.18] 104.0 
2 Stroke 




pulmonary disease 3,104,330 (5.56%) [5.55 – 5.56] 43.9 
4 Lower respiratory infections 3,051,990 (5.46%) [5.46 – 5.47] 43.1 
5 
Trachea, bronchus, lung 
cancers 1,599,560 (2.86%) [2.86 – 2.87] 22.6 
6 HIV/AIDS 1,533,760 (2.75%) [2.74 – 2.75] 21.7 
7 Diarrhoeal diseases 1,497,720 (2.68%) [2.68 – 2.69] 21.2 
8 Diabetes mellitus 1,497,370 (2.68%) [2.68 – 2.68] 21.2 
9 Road injury 1,254,530 (2.25%) [2.24 – 2.25] 17.7 
10 Hypertensive heart disease 
1,141,210 (2.041%) [2.04 – 
2.05] 16.1 
   
Table 3: Global CVD DALY’s Lost: 2000 and 2012.  
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All Cause 
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Rheumatic heart disease 
Hypertensive heart disease 






















Congenital heart anomalies 20,291,404 (0.7%) 19,784,491 (1.3%) 























  2000 
Rank Cause 
% 
DALYs DALYs per 100,000 population 
0 All Causes 100 46913.5 
1 Lower respiratory infections 7.3 3402.0 
2 Diarrhoeal diseases 5.6 2624.5 
3 Ischaemic heart disease 5.0 2322.5 
4 Stroke 4.4 2043.3 
5 Preterm birth complications 4.3 2015.9 
6 Birth asphyxia and birth trauma 3.6 1666.1 
7 HIV/AIDS 3.5 1659.8 
8 Chronic obstructive pulmonary disease 3.1 1460.2 
9 Malaria 2.7 1277.7 
10 Road injury 2.4 1129.0 
  2012 
Rank Cause 
% 
DALYs DALYs per 100,000 population 
0 All Causes 100 38779.9 
1 Ischaemic heart disease 6.0 2342.1 
2 Lower respiratory infections 5.4 2075.7 
3 Stroke 5.2 1997.7 
4 Preterm birth complications 3.9 1515.2 
5 Diarrhoeal diseases 3.6 1409.5 
6 Chronic obstructive pulmonary disease 3.4 1305.6 
7 HIV/AIDS 3.4 1299.0 
8 Road injury 2.9 1112.6 
9 Unipolar depressive disorders 2.8 1081.2 
10 Birth asphyxia and birth trauma 2.7 1054.3 
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Figure 1: CVD Mortality in 2000 and 2012 by WHO region. 
 
Figure 2: CVD and NCD mortality in 2000 and 2012 by World Bank Economic 
Regions. 
 
 All LMI regions demonstrate a statistically significant increase (p value <0.001). 
 
 Figure 3a: Mortality by Sex and Age in 2012.   
 
Figure 3b: CVD mortality in Males by Age and WHO region in 2012.  
 
Figure 3c: CVD Mortality in Females by Age and WHO region in 2012. 
 
Figure 4: DALYs lost to CVD and NCD in 2000 and 2012 by World Bank Economic 
Regions 
 
Figure 5a: DALYs lost to CVD by Sex and Age in 2012.   
 
Figure 5b: DALYs lost to CVD in Males by Age and WHO region in 2012.  
 
Figure 5c: DALYs lost to CVD in Females by Age and WHO region in 2012. 
 
Figure 6a: WHO/World Bank Regions contribution to IHD DALYs lost in 2000.  
 
Figure 6b: WHO/World Bank regions contribution to IHD DALYs lost in 2012. 
 
 
